Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
Background: Tyrosine kinases are highly expressed in platelets and play an important role in their activation process. Some studies have reported the blocking effects of tyrosine kinase inhibitors on different platelet functions. Objectives: Evaluate the effects of nilotinib on platelets aggregation...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | Leukemia Research Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048918300074 |
| _version_ | 1818989086089674752 |
|---|---|
| author | Alauldeen Mudhafar Zubair Alqasim Ghasaq Mohsin Obaid Yusra Ghaith Yaseen Alaa Fadhil Alwan |
| author_facet | Alauldeen Mudhafar Zubair Alqasim Ghasaq Mohsin Obaid Yusra Ghaith Yaseen Alaa Fadhil Alwan |
| author_sort | Alauldeen Mudhafar Zubair Alqasim |
| collection | DOAJ |
| description | Background: Tyrosine kinases are highly expressed in platelets and play an important role in their activation process. Some studies have reported the blocking effects of tyrosine kinase inhibitors on different platelet functions. Objectives: Evaluate the effects of nilotinib on platelets aggregation in 42 patients with chronic phase of CML and correlate the results with clinical and hematological parameters: age, complete blood count and presentation. Patients and methods: This study was conducted on 42 patients diagnosed as Chronic Phase of Chronic Myeloid Leukemia based on clinical, morphological and cytogenetic study. All patients were on Nilotinib treatment and were attending the National Center of Hematology in Baghdad. About 9 mL of venous blood sample were collected from each patient and control subjects, samples divided into 3 parts for complete blood count, platelet aggregation test and PT and aPTT. Results: The mean age was 41.3 ± 1.7 (mean ± SEM) years old. M:F ratio of 1.2:1. Mean duration of nilotinib therapy(1.4 years). All patients had normal PT and aPTT.Only 16 (38%) patients had abnormal aggregation response to epinephrine, but there was no statistically significant differences with control group. Conclusion: Nilotinib had no adverse effect on platelet function nor patients clotting tests. Keywords: Chronic Myeloid Leukemia, Chronic phase, Nilotinib, Platelet function, Aggregometry |
| first_indexed | 2024-12-20T19:32:53Z |
| format | Article |
| id | doaj.art-76d19e3f56394049ba3fe85a6b0e6cfb |
| institution | Directory Open Access Journal |
| issn | 2213-0489 |
| language | English |
| last_indexed | 2024-12-20T19:32:53Z |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj.art-76d19e3f56394049ba3fe85a6b0e6cfb2022-12-21T19:28:44ZengElsevierLeukemia Research Reports2213-04892019-01-01114650Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phaseAlauldeen Mudhafar Zubair Alqasim0Ghasaq Mohsin Obaid1Yusra Ghaith Yaseen2Alaa Fadhil Alwan3University of Mustansiriyah, College of Medicine, Department of Pathology, Baghdad, Iraq; Corresponding author.Al-Yarmouk Teaching Hospital, Laboratory Department, Baghdad, IraqUniversity of Mustansiriyah, National Center of Hematology, Baghdad, IraqUniversity of Mustansiriyah, National Center of Hematology, Baghdad, IraqBackground: Tyrosine kinases are highly expressed in platelets and play an important role in their activation process. Some studies have reported the blocking effects of tyrosine kinase inhibitors on different platelet functions. Objectives: Evaluate the effects of nilotinib on platelets aggregation in 42 patients with chronic phase of CML and correlate the results with clinical and hematological parameters: age, complete blood count and presentation. Patients and methods: This study was conducted on 42 patients diagnosed as Chronic Phase of Chronic Myeloid Leukemia based on clinical, morphological and cytogenetic study. All patients were on Nilotinib treatment and were attending the National Center of Hematology in Baghdad. About 9 mL of venous blood sample were collected from each patient and control subjects, samples divided into 3 parts for complete blood count, platelet aggregation test and PT and aPTT. Results: The mean age was 41.3 ± 1.7 (mean ± SEM) years old. M:F ratio of 1.2:1. Mean duration of nilotinib therapy(1.4 years). All patients had normal PT and aPTT.Only 16 (38%) patients had abnormal aggregation response to epinephrine, but there was no statistically significant differences with control group. Conclusion: Nilotinib had no adverse effect on platelet function nor patients clotting tests. Keywords: Chronic Myeloid Leukemia, Chronic phase, Nilotinib, Platelet function, Aggregometryhttp://www.sciencedirect.com/science/article/pii/S2213048918300074 |
| spellingShingle | Alauldeen Mudhafar Zubair Alqasim Ghasaq Mohsin Obaid Yusra Ghaith Yaseen Alaa Fadhil Alwan Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase Leukemia Research Reports |
| title | Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase |
| title_full | Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase |
| title_fullStr | Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase |
| title_full_unstemmed | Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase |
| title_short | Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase |
| title_sort | effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase |
| url | http://www.sciencedirect.com/science/article/pii/S2213048918300074 |
| work_keys_str_mv | AT alauldeenmudhafarzubairalqasim effectsofnilotinibonplateletfunctioninpatientswithchronicmyeloidleukemiainchronicphase AT ghasaqmohsinobaid effectsofnilotinibonplateletfunctioninpatientswithchronicmyeloidleukemiainchronicphase AT yusraghaithyaseen effectsofnilotinibonplateletfunctioninpatientswithchronicmyeloidleukemiainchronicphase AT alaafadhilalwan effectsofnilotinibonplateletfunctioninpatientswithchronicmyeloidleukemiainchronicphase |